Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AESOP: GC4419 for Esophagitis in Lung Cancer
NCT04225026Phase 2Terminated
- Sponsor
- Galera Therapeutics, Inc.
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avasopasem manganese in radiation-induced esophagitis, sponsored by Galera Therapeutics, Inc.. Started Dec 2019; status: terminated.
02
Drugs
avasopasem manganese
03
Conditions
radiation-induced esophagitis
Beyond the preview
Go deeper on NCT04225026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04225026.